The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
IDO1 as a mechanism of adaptive immune resistance to anti-PD1 monotherapy in HNSCC.
 
Lori J Wirth
Consulting or Advisory Role - Amgen; Blueprint Medicines; Eisai; Loxo; Merck
Research Funding - Bayer (Inst); Eisai (Inst); Merck (Inst)
 
Barbara Burtness
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Debiopharm Group; MedImmune; Merck; VentiRx
Research Funding - Merck
 
Ranee Mehra
Employment - GlaxoSmithKline (I)
Stock and Other Ownership Interests - GlaxoSmithKline (I)
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Genentech; Innate Pharma; Novartis
Research Funding - Genentech
Travel, Accommodations, Expenses - Mirati Therapeutics
 
Jessica Ruth Bauman
No Relationships to Disclose
 
Jina Lee
No Relationships to Disclose
 
Nicole Marie Stauffer Smith
No Relationships to Disclose
 
Armida Lefranc-Torres
No Relationships to Disclose
 
William H. Westra
Consulting or Advisory Role - AstraZeneca; Merck
 
Justin A. Bishop
No Relationships to Disclose
 
William C Faquin
Expert Testimony - Crico
 
Derrick T. Lin
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Tesaro (Inst)
 
Sara I. Pai
Consulting or Advisory Role - Abbvie; AstraZeneca/MedImmune; Merck
Research Funding - AstraZeneca/MedImmune (Inst); Merck (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca/MedImmune; Merck